Yarrow Bioscience (YARW) Non-Current Debt (2019 - 2021)
Yarrow Bioscience's (YARW) quarterly Non-Current Debt came in at $33.3 million in Q1 2021, up 1.39% YoY from $32.8 million in Q1 2020, and little changed on a QoQ basis from $33.2 million in Q4 2020.
Yarrow Bioscience (YARW) Non-Current Debt (2019 - 2021) Analysis & Trends
Yarrow Bioscience (YARW) has 3 years of Non-Current Debt data on file, last reported at $33.3 million in Q1 2021.
- Quarterly Non-Current Debt rose 1.39% year-over-year to $33.3 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $33.3 million (up 1.39% YoY) and the FY2020 annual result came in at $33.2 million, up 1.37% from the prior year.
- Non-Current Debt held at $33.3 million in Q1 2021, from $33.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $33.3 million in Q1 2021 to a low of $32.7 million in Q4 2019.
- A 3-year average of $33.0 million and a median of $33.0 million in 2020 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2020 — Non-Current Debt grew 1.37% — and 2021, when it advanced 1.39%.
- Tracing YARW's Non-Current Debt over 3 years: stood at $32.7 million in 2019, then rose by 1.37% to $33.2 million in 2020, then climbed by 0.3% to $33.3 million in 2021.
- The last three Non-Current Debt figures came in at $33.3 million (Q1 2021), $33.2 million (Q4 2020), and $33.0 million (Q3 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 8.96 Bn |
| 10 | Yarrow Bioscience | 30.89 Mn | 7.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 33.27 Mn |
| Dec 31, 2020 | 33.17 Mn |
| Sep 30, 2020 | 33.02 Mn |
| Jun 30, 2020 | 32.92 Mn |
| Mar 31, 2020 | 32.82 Mn |
| Dec 31, 2019 | 32.73 Mn |